Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hurwitz, S. J.
Right arrow Articles by Slapak, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hurwitz, S. J.
Right arrow Articles by Slapak, C. A.
Related Collections
Right arrow Neoplasia
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes

SJ Hurwitz, M Terashima, N Mizunuma and CA Slapak

Division of Cancer Pharmacology, The Dana-Farber Cancer Institute and The Harvard Medical School, Boston, MA, USA.

The U-A10 cell line, a doxorubicin-selected variant of human U-937 myeloid leukemia cells, exhibits a redistribution of anthracyclines into a expanded vesicular compartment. The acidic nature of this compartment was confirmed by vital staining with a pH sensitive dye, LysoSensor yellow/blue DND-160. Identification of the vesicular compartment was performed by immunofluorescence analysis. Staining for the LAMP-1 and LAMP-2 antigens showed that the vesicles are enlarged lysosomes that are eccentrically placed near the nucleus of U-A10 cells. By contrast, the expression of the multidrug resistance- associated protein and the P-glycoprotein was observed predominately on the plasma membrane of the drug-resistant cells. The accumulation of daunorubicin into cellular compartments was quantified using radiolabeled drug. Exposing cells to 3[H]-daunorubicin and then isolating intact nuclei showed that nuclei from U-A10 cells accumulated twofold to threefold less anthracycline than nuclei from U-937 cells. However, when nuclei were isolated first and then exposed to 3[H]- daunorubicin, little difference in net nuclear drug accumulation was detected. Cytoplasts prepared from U-A10 and U-937 cells were exposed to 3[H]-daunorubicin to measure cytoplasmic drug accumulation. At external daunorubicin concentrations of 100 ng/mL or higher, cytoplasts from U-A10 cells accumulated significantly more daunorubicin than cytoplasts from U-937 cells. Moreover, studies with the lysosomotropic agent chloroquine showed that U-A10 cells accumulated twofold more chloroquine and showed twofold enhanced sensitivity to this agent as compared with parental U-937 cells. Fluorescence microscopy showed that chloroquine affects vesicular anthracycline sequestration in U-A10 cells with an associated increase in daunorubicin nuclear fluorescence. Although chloroquine did not alter anthracycline cytotoxicity in parental cells, it restored daunorubicin and doxorubicin sensitivity to U-A10 cells. Taken together, these studies demonstrate that U-A10 cells exhibit a redistribution of the lysosomal compartment. The trapping of drug into an expanded acidic vesicular compartment results in decreased nuclear drug accumulation and decreased cytotoxicity. Lysosomotropic agents, such as chloroquine, warrant further study as modulators of this acquired drug-resistance phenotype.

Volume 89, Issue 10, pp. 3745-3754, 05/15/1997
Copyright © 1997 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
X. Xu, R. Sutak, and D. R. Richardson
Iron Chelation by Clinically Relevant Anthracyclines: Alteration in Expression of Iron-Regulated Genes and Atypical Changes in Intracellular Iron Distribution and Trafficking
Mol. Pharmacol., March 1, 2008; 73(3): 833 - 844.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
J. Liu, W. Lu, D. Reigada, J. Nguyen, A. M. Laties, and C. H. Mitchell
Restoration of Lysosomal pH in RPE Cells from Cultured Human and ABCA4-/- Mice: Pharmacologic Approaches and Functional Recovery
Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 772 - 780.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Salvatorelli, S. Guarnieri, P. Menna, G. Liberi, A. M. Calafiore, M. A. Mariggio, A. Mordente, L. Gianni, and G. Minotti
Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart: RELATIVE IMPORTANCE OF VESICULAR SEQUESTRATION AND IMPAIRED EFFICIENCY OF ELECTRON ADDITION
J. Biol. Chem., April 21, 2006; 281(16): 10990 - 11001.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
R. Cairns, I. Papandreou, and N. Denko
Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment
Mol. Cancer Res., February 1, 2006; 4(2): 61 - 70.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X. Xu, H. L. Persson, and D. R. Richardson
Molecular Pharmacology of the Interaction of Anthracyclines with Iron
Mol. Pharmacol., August 1, 2005; 68(2): 261 - 271.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
F. Luciani, M. Spada, A. De Milito, A. Molinari, L. Rivoltini, A. Montinaro, M. Marra, L. Lugini, M. Logozzi, F. Lozupone, et al.
Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs
J Natl Cancer Inst, November 17, 2004; 96(22): 1702 - 1713.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Duvvuri, Y. Gong, D. Chatterji, and J. P. Krise
Weak Base Permeability Characteristics Influence the Intracellular Sequestration Site in the Multidrug-resistant Human Leukemic Cell Line HL-60
J. Biol. Chem., July 30, 2004; 279(31): 32367 - 32372.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. van Zon, M. H. Mossink, M. Schoester, R. J. Scheper, P. Sonneveld, and E. A. C. Wiemer
Efflux Kinetics and Intracellular Distribution of Daunorubicin Are Not Affected by Major Vault Protein/Lung Resistance-Related Protein (Vault) Expression
Cancer Res., July 15, 2004; 64(14): 4887 - 4892.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
X. Zheng, P. M. Chou, B. L. Mirkin, and A. Rebbaa
Senescence-initiated Reversal of Drug Resistance: Specific Role of Cathepsin L
Cancer Res., March 1, 2004; 64(5): 1773 - 1780.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. C. Kwok and D. R. Richardson
Examination of the Mechanism(s) Involved in Doxorubicin-Mediated Iron Accumulation in Ferritin: Studies Using Metabolic Inhibitors, Protein Synthesis Inhibitors, and Lysosomotropic Agents
Mol. Pharmacol., January 1, 2004; 65(1): 181 - 195.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Gong, M. Duvvuri, and J. P. Krise
Separate Roles for the Golgi Apparatus and Lysosomes in the Sequestration of Drugs in the Multidrug-resistant Human Leukemic Cell Line HL-60
J. Biol. Chem., December 12, 2003; 278(50): 50234 - 50239.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
J. F. Perez, M. C. Ruiz, and F. Michelangeli
Simultaneous measurement and imaging of intracellular Ca2+ and H+ transport in isolated rabbit gastric glands
J. Physiol., December 15, 2001; 537(3): 735 - 745.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. Okumura, Z.-S. Chen, M. Sakou, T. Sumizawa, T. Furukawa, M. Komatsu, R. Ikeda, H. Suzuki, K. Hirota, T. Aikou, et al.
Reversal of P-Glycoprotein and Multidrug-Resistance Protein-Mediated Drug Resistance in KB Cells by 5-O-Benzoylated Taxinine K
Mol. Pharmacol., April 13, 2001; 58(6): 1563 - 1569.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
M. A. Cabrita, T. C. Hobman, D. L. Hogue, K. M. King, and C. E. Cass
Mouse Transporter Protein, a Membrane Protein That Regulates Cellular Multidrug Resistance, Is Localized to Lysosomes
Cancer Res., October 1, 1999; 59(19): 4890 - 4897.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Chen, M. Schindler, and S. M. Simon
A Mechanism for Tamoxifen-mediated Inhibition of Acidification
J. Biol. Chem., June 25, 1999; 274(26): 18364 - 18373.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. Altan, Y. Chen, M. Schindler, and S. M. Simon
Tamoxifen inhibits acidification in cells independent of the estrogen receptor
PNAS, April 13, 1999; 96(8): 4432 - 4437.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. A. Hazlehurst, N. E. Foley, M. C. Gleason-Guzman, M. P. Hacker, A. E. Cress, L. W. Greenberger, M. C. De Jong, and W. S. Dalton
Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line
Cancer Res., March 1, 1999; 59(5): 1021 - 1028.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020